Background: There is no consensus on the most effective treatments of pulmonary arterial
hypertension (PAH). Our objective was to compare effects of medications for PAH. Methods …

Background The evolution in pulmonary arterial hypertension (PAH) management has been
summarised in three iterations of the European Society of Cardiology/European Respiratory …

Chronic obstructive pulmonary disease-associated pulmonary hypertension (COPD-PH) is
an increasingly recognised condition which contributes to worsening dyspnoea and poor …

The number of women of childbearing age with cardiovascular disease (CVD) is growing
because of increased survival of children with congenital heart disease. More women are …

Background Up to 1% of the world population and 10% of all persons over age 65 suffer
from pulmonary hypertension (PH). The latency from the first symptom to the diagnosis is …

Performing longitudinal and consistent risk assessments for patients with pulmonary arterial
hypertension (PAH) is important to help guide treatment decisions to achieve early on and …

The treatment landscape for PAH has evolved dramatically over the past 30 years. 3
Medications targeting the endothelin, nitric oxide, and prostacyclin pathways have been …

Pulmonary hypertension (PH) is a global health issue with a prevalence of 10% in ages> 65
years. Right heart failure (RHF) is the main cause of death in PH. We have previously shown …

Introduction Cardiovascular diseases present a great burden for survivors of hematologic
malignancy (HM). However, the effect of pulmonary hypertension (PH) on the clinical …

Purpose Chronic obstructive pulmonary disease (COPD)-related pulmonary hypertension
(PH) is one of the most common comorbidities of COPD, and often leads to a worse …